Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Neuroleptic

or [[:Category:Catecholamines|Catecholamine]]

Use the filters below to narrow your results.

Asenapine (1) · Buprenorphine (1) · Butorphanol (1) · Chlorpromazine (1) · Clozapine (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Droperidol (1) · Epinephrine (adrenaline) (1) · Ethylmorphine (1) · Fentanyl (1) · Fluphenazine (1) · Hydrocodone (1) · Hydromorphone (1) · Iloperidone (1) · Levorphanol (1) · Loxapine (1) · Lurasidone (1) · Meperidine (1) · Methadone (1) · Molindone (1) · Nalbuphine (1) · Oxymorphone (1) · Paliperidone (1) · Papaverine (1) · Pentazocine (1) · Perphenazine (1) · Pimozide (1) · Tapentadol (1) · Thioridazine (1) · Thiothixene (1) · Trifluoperazine (1) · Ziprasidone (1)

None (5) · (multiple, generic dominant) (1) · Clozaril (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · EpiPen, EpiPen Jr, Auvi-Q, Adrenaclick, Symjepi; many generic (1) · Fanapt (1) · Geodon (1) · Inapsine (1) · Invega (1) · Latuda (1) · Loxitane (1) · Mellaril (1) · Moban (1) · Navane (1) · Nubain (1) · Nucynta (1) · Opana (1) · Orap (1) · Prolixin (1) · Saphris (1) · Stadol (1) · Stelazine (1) · Suboxone (1) · Talwin (1) · Thorazine (1) · Trilafon (1) · Vicodin (1)

Butyrophenone D2 antagonist (1) · D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) · D2/5-HT2A antagonist (1) · D2/5-HT2A antagonist; 5-HT7 antagonist (1) · D2/5-HT2A antagonist; active metabolite of risperidone (1) · D2/5-HT2A antagonist; SRI and NRI (1) · Dibenzoxazepine D2/5-HT2 antagonist (1) · Dihydroindolone D2 antagonist (1) · Diphenylbutylpiperidine D2 antagonist (1) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) · Multi-receptor antagonist; low D2 affinity (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phenothiazine D2 antagonist (4) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Thioxanthene D2 antagonist (1) · '"`UNIQ--vote-00000E4A-QINU`"' The narrow safe-bolus window for IV use (sharp risk of arrhythmia, hypertensive emergency, intracerebral hemorrhage) is why anaphylaxis dosing is '''IM, not IV''', outside critical care'"`UNIQ--ref-00000E4B-QINU`"'. (1)

None (33) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000E4C-QINU`"', '"`UNIQ--vote-00000E4D-QINU`"', '"`UNIQ--vote-00000E4E-QINU`"', '"`UNIQ--vote-00000E4F-QINU`"', '"`UNIQ--vote-00000E50-QINU`"', '"`UNIQ--vote-00000E51-QINU`"' (1)

None (33) · Adult: 15–60 mg every 4 hours as needed. (1) · Anaphylaxis IM 0.3-0.5 mg (adult) into lateral thigh, repeat q5-15 minutes prn; pediatric 0.01 mg/kg IM (max 0.3 mg, max 0.5 mg in adolescents); cardiac arrest 1 mg IV/IO q3-5 minutes; severe asthma neb 0.1 mg/kg up to 5 mg; never IV bolus for anaphylaxis outside critical care (1)

None (33) · Auto-injectors 0.15 mg (Jr/pediatric), 0.3 mg (adult); 1 mg/mL (1:1,000) ampules for IM/SC use; 0.1 mg/mL (1:10,000) for IV use; 2.25% racemic nebulizer (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (33) · 360 mg/day (1) · Indication-specific; ACLS no fixed cumulative ceiling (1)

None (33) · endotracheal (legacy ACLS (1) · IM (1) · intracardiac (historical only) (1) · IV (1) · nebulized (1) · not preferred) (1) · PO (only formulation marketed in the US). (1) · SC (less common) (1)

None (33) · 30–60 min (PO) (1) · IM: 5-10 minutes; IV: seconds; nebulized: 5-10 minutes (1)

None (33) · 4–6 hours (1) · 5-15 minutes (1)

None (33) · 2.5–3 hours (1) · ~2 minutes'"`UNIQ--ref-00000E52-QINU`"' (1)

None (33) · IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)'"`UNIQ--ref-00000E53-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (33) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Used in life-threatening obstetric anaphylaxis without hesitation; benefits clearly outweigh.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (33) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (1)